Recently published
This page was published on [date_placeholder].
Recently updated
This page was updated on [date_placeholder]. See page history for details.
Purpose
This guidance outlines the types of variations and changes that can be made to biological medicines currently on the Australian Register of Therapeutic Goods (ARTG).
Category 1 applications are not covered by this guidance. These require evaluation of a full dataset, or any combination of quality, nonclinical, clinical and bioequivalence data. See the Prescription medicines registration process for information on how to lodge a Category 1 application.
Guidance
This guidance is presented as downloadable files because of its length.
Downloads
Page history
Minor amendments to phrasing and layout. Hyperlinks updated.
Amended title.
Additional information on:
- variation types that are associated with a mandatory PAR field update,
- changes that do not need to be notified to the TGA,
- new variation types (Associated changes, SARO).
Minor clarifications and corrections to phrasing and layout.
Minor fixes to typographical errors.
Inclusion of notifiable variations to registered medicines. Minor amendments to phrasing and layout.
Original publication.
Minor amendments to phrasing and layout. Hyperlinks updated.
Amended title.
Additional information on:
- variation types that are associated with a mandatory PAR field update,
- changes that do not need to be notified to the TGA,
- new variation types (Associated changes, SARO).
Minor clarifications and corrections to phrasing and layout.
Minor fixes to typographical errors.
Inclusion of notifiable variations to registered medicines. Minor amendments to phrasing and layout.
Original publication.